Full-Time

Senior Medical Science Liaison

Hepatology

Updated on 9/4/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$138k - $198k/yr

+ Bonus

Chicago, IL, USA

Remote

Travel up to 60% of the time is required.

PharmD, PhD, MD

Category
Biology & Biotech
Required Skills
Risk Management

Get referred to Mallinckrodt

See people who can refer or advise you

Requirements
  • An advanced scientific degree such as Doctor of Medicine, Doctor of Optometry, Doctor of Philosophy, or Doctor of Pharmacy, or equivalent experience.
  • At least 3 years of experience in the pharmaceutical industry, another healthcare environment, or equivalent experience.
  • Demonstrated ability to access and develop relationships with high-level stakeholders.
  • Ability to effectively communicate scientific content through one-to-one meetings, small-group interactions, and written materials.
  • Demonstrated ability to manage projects, including timelines, stakeholder management, and risk control.
  • Demonstrated ability to build and facilitate effective training programs.
  • Experience in a mentoring role.
  • Ability to independently research responses to scientific inquiries.
  • Ability to identify and build effective plans for engaging key opinion leaders in the territory.
  • Ability to collaborate effectively with internal departments.
  • A valid driver's license is required.
  • Ability to work independently, focus on patients and partners, learn, solve problems, build relationships, adapt, think strategically, and work as part of a team.
Responsibilities
  • Develop relationships with key opinion leaders in the assigned territory through scientific exchange.
  • Engage in scientific dialogue and communicate scientific content in response to key opinion leader requests.
  • Assess key opinion leader alignment with the scientific platform to inform territory and medical strategy.
  • Develop key opinion leader advocates and collaborators within the assigned territory.
  • Compliantly support company-sponsored research, investigator-initiated studies, and publications associated with company products.
  • Coach and support Medical Science Liaisons in gaining access to key opinion leaders and developing engagement strategies.
  • Research and identify key opinion leaders and focus key opinion leaders for the assigned therapeutic area.
  • Build and execute a territory plan to achieve key opinion leader engagement goals.
  • Complete pre-call planning independently for effective key opinion leader interactions.
  • Develop key opinion leader relationships and engage in scientific exchange with payers as needed.
  • Stay current with emerging scientific literature and clinical data and translate the data into applicable knowledge.
  • Respond to Medical Information Request Forms with initial contact within two days and a full answer within three weeks.
  • Ensure appropriate dissemination of clinical and scientific information regarding FDA-approved and pipeline products in a timely, ethical, and customer-focused manner.
  • Collect scientific and clinical insights, including new data, competitive information, and customer insights, to optimize communications and coordinated activities across the organization.
  • Respond to requests for directed insights within the expected timeframe.
  • Participate in advisory boards.
  • Monitor team insights by adding tags and classifying insights for review and organization.
  • Contribute scientific content and build materials to support projects or initiatives.
  • Run projects independently, including project planning, stakeholder engagement, risk management, and quality control.
  • Coordinate the work of others and provide coaching to achieve project goals.
  • Mentor Medical Science Liaisons.
  • Lead congress planning and reporting.
  • Build training materials using effective instructional design techniques.
  • Provide ongoing scientific and medical training or support within the Medical Science Liaison team and to internal partners.
Desired Qualifications
  • At least 2 years of leadership experience.
  • Thorough knowledge of medicine, treatment guidelines, clinical research processes, customer strategies, FDA promotional guidelines, regulations, and ethical guidelines.
  • Prior experience in hepatology, nephrology, or transplantation.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 Acthar Gel net sales reached $205 million, up 17%.
  • August 11, 2026 guidance raised, with 2026 pro forma sales up to $2.0 billion.
  • Management now plans a 2027 NYSE listing after integration progress.

What critics are saying

  • Maine DEP sued Mallinckrodt US LLC on August 25, 2026 over Orrington cleanup failures.
  • Keenova reported a $221 million Q2 2026 loss from continuing operations.
  • A failed 2027 NYSE listing traps Keenova with debt, litigation, and reputational damage.

What makes Mallinckrodt unique

  • Keenova’s Acthar Gel and XIAFLEX franchises drive branded rare-disease cash flows.
  • July 31, 2025 Endo merger combined branded therapies with scale and synergies.
  • November 2025 Par Health spinout left a pure-play specialty therapeutics company.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Maine Morning Star
Aug 27th, 2026
Maine DEP sues Mallinckrodt over failures to clean up contaminated Orrington site.

Maine DEP sues Mallinckrodt over failures to clean up contaminated Orrington site. The Department of Environmental Protection has filed a lawsuit against Mallinckrodt US LLC, accusing the company of failing to clean up mercury contamination at its site in Orrington. The department filed the complaint in Penobscot Superior Court Tuesday, and in court records the department said the company has stopped "meaningful work" at the site despite department orders and notices of violations. Jesse Graham is the co-director of the Maine People's Alliance - which, independent from the state enforcement actions, sued Mallinckrodt over the contamination in federal court in 2000. "We have for a long time been calling for the thorough cleanup of that site, and we have definitely been disappointed that Mallinckrodt has not cleaned it up to the standards that the Maine DEP has set," Graham said. "We fully support the Maine DEP continuing to pressure them and whatever legal tactics they need to do to compel them to finish and do a thorough cleanup of all the pollution that Mallinckrodt has left on the site." Considered the most contaminated site in Maine, the property is the former HoltraChem chloralkali manufacturing facility. Located adjacent to the Penobscot River, the facility operated from 1967 through 2000, and manufactured caustic soda, chlorine bleach and pesticides. In court documents, the department said Mallinckrodt has complained about the difficulties and high costs of cleaning up the site. But, the department said, "this is no excuse for Mallinckrodt's ongoing failure to adhere to the cleanup standards and other requirements of the orders." The department is asking the court for civil penalties, and to order Mallinckrodt to comply with all department orders and submit a plan to remove all soil and solid materials from the site. Attempts to reach someone who could speak on behalf of Mallinckrodt were unsuccessful. The DEP and the U.S. Environmental Protection Agency first began pursuing clean up at the site in the mid-1980s, including negotiations with the company in 2002. But after failing to reach an agreement, in 2008 the department issued a unilateral cleanup order for the site. But Mallinckrodt appealed that order, first to the Board of Environmental Protection, and then in state courts. Ultimately, the state supreme court upheld the department's order in 2014. The department issued notices of violations to Mallinckrodt in May and October of 2025, over the ongoing issues, but said the company still failed to address the shortcomings of their proposed cleanup plans. There is also the federal court case filed by the Maine People's Alliance, which is separate from the state proceedings involving the department. In 2022, Mallinckrodt settled the federal case, and agreed to pay at least $187 million to address mercury pollution in the Penobscot River. Graham said some of that agreed-up work is underway now, as Mallinckrodt adds sand to several coves along the river with high levels of mercury, a process known as "capping."

Charter Communications
Aug 27th, 2026
DEP sues to compel cleanup of 'most contaminated site in Maine'

DEP sues to compel cleanup of 'most contaminated site in Maine' BY Susan Cover Maine PUBLISHED 10:13 AM ET Aug. 27, 2026 AUGUSTA - State officials are escalating action against a company they say has failed to clean up "the most contaminated site in Maine" after more than 20 years of lawsuits. The Maine Department of Environmental Protection filed a formal complaint Tuesday in Penobscot County Superior Court against Mallinckrodt US LLC. The state alleges that the company has failed to clean up the former HoltraChem site on the Penobscot River in Orrington. The site "discharged to the environment tons of mercury and thousands of tons of mercury-contaminated brine-sludge, substances that are defined as hazardous wastes," according to the lawsuit. The facility made chemicals commonly used in the pulp and paper industry, according to DEP. It operated under various owners from 1967 to 2000. The company did not respond to a request for comment. The suit says the facility covered about 235 acres near the river, 77 of which were affected by the production. The site included five landfills, a manufacturing facility and waste piles. In the mid-1980s, the U.S. Environmental Protection Agency and the state began investigating the site and calling for remediation. According to the suit, in 2000, the Maine People's Alliance and the Natural Resources Defense Council filed a lawsuit against the company alleging that the company "discharged mercury from the site into the Penobscot River and that these discharges resulted in an imminent and substantial danger to public health and the environment." A court ordered the company to come up with a remediation plan. The latest lawsuit asks the court to remove contaminated soil and industrial sewer lines, assess civil penalties and require the company to comply with all DEP orders.

Portland Press Herald
Aug 25th, 2026
Maine DEP sues company over cleanup of contaminated Orrington site.

Maine DEP sues company over cleanup of contaminated Orrington site. Mallinckrodt US LLC operated a chemical manufacturing plant along the Penobscot River in Orrington that discharged up to a dozen metric tons of mercury in the late 1960s and early 1970s. Community: Posted 7:54 PM Updated at 7:54 PM The Maine Department of Environmental Protection is suing the owners of a site in Orrington, alleging they've failed to properly clean up contamination. The Maine DEP announced the legal action in Penobscot Superior Court against Mallinckrodt US LLC on Tuesday. The department is seeking injunctive relief and civil penalties. The company operated a chemical manufacturing plant along the Penobscot River in Orrington between 1967 and 1982. While under Mallinckrodt's control, the site discharged between six and 12 metric tons of mercury in the late 1960s and early 1970s, according to one court-ordered study. Please add a subscription to your account to access this story. Choose a plan to keep reading. Starter Digital $1 for 4 weeks * | 4 weeks of access for $1 * | Full access to our websites, ePapers and app * | Newsletters, archives, puzzles and games * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household Annual Digital $99 per year Billed annually - Save 56% * | One year of access for $99 * | Full access to our websites, ePapers and app * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.